Search results for "E2F"

showing 10 items of 37 documents

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

2018

AbstractPurpose: This study aimed to identify biomarkers of resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancers treated with prolonged neoadjuvant letrozole.Experimental Design: We performed targeted DNA and RNA sequencing in 68 ER+ breast cancers from patients treated with preoperative letrozole (median, 7 months).Results: Twenty-four tumors (35%) exhibited a PEPI score ≥4 and/or recurred after a median of 58 months and were considered endocrine resistant. Integration of the 47 most upregulated genes (log FC > 1, FDR < 0.03) in letrozole-resistant tumors with transcription-binding data showed significant overlap with 20 E2F4-regulated genes (P =…

0301 basic medicineCancer ResearchBreast NeoplasmsE2F4 Transcription FactorArticle03 medical and health sciences0302 clinical medicineText miningDownregulation and upregulationCell Line TumorBiomarkers TumormedicineHumansEndocrine systemProtein Kinase InhibitorsE2F4GeneAgedCell ProliferationAged 80 and overAromatase Inhibitorsbusiness.industryGene Expression ProfilingLetrozoleEndocrine therapyComputational BiologyMiddle AgedEMTREE drug terms: aromatase inhibitorcyclin dependent kinase 4cyclin dependent kinase 6cyclin dependent kinase inhibitorfulvestrantletrozolepaclitaxelpalbociclibtranscription factor E2F4estrogen receptorletrozoleprotein kinase inhibitortranscription factor E2F4transcriptometumor marker030104 developmental biologyReceptors EstrogenOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisLetrozoleMutationRetreatmentCancer researchFemaleTranscriptomebusinessmedicine.drug
researchProduct

Role of p27Kip1 as a transcriptional regulator

2018

The protein p27Kip1 is a member of the Cip/Kip family of cyclin-dependent kinase (Cdk) inhibitors. It interacts with both the catalytic and the regulatory subunit (cyclin) and introduces a region into the catalytic cleave of the Cdk inducing its inactivation. Its inhibitory capacity can be modulated by specific tyrosine phosphorylations. p27Kip1 also behaves as a transcriptional regulator. It associates with specific chromatin domains through different transcription factors. ChIP on chip, ChIP-seq and expression microarray analysis allowed the identification of the transcriptional programs regulated by p27Kip1. Thus, important cellular functions as cell division cycle, respiration, RNA proc…

0301 basic medicinep27Kip1Review03 medical and health sciencesTranscriptional regulationCyclin-dependent kinaseTranscription (biology)Gene expressionTranscriptional regulationcancertranscriptional regulationNeurodegenerationCàncerTranscription factorE2F4CancerbiologyChemistryMalalties neurodegenerativesneurodegenerationNeurodegenerative DiseasesChIP-on-chipExpressió gènicaCell biologyChromatin030104 developmental biologyOncologybiology.proteinGene expressionOncotarget
researchProduct

DNA damage-induced cell death by apoptosis

2006

Following the induction of DNA damage, a prominent route of cell inactivation is apoptosis. During the last ten years, specific DNA lesions that trigger apoptosis have been identified. These include O6-methylguanine, base N-alkylations, bulky DNA adducts, DNA cross-links and DNA double-strand breaks (DSBs). Repair of these lesions are important in preventing apoptosis. An exception is O6-methylguanine-thymine lesions, which require mismatch repair for triggering apoptosis. Apoptosis induced by many chemical genotoxins is the consequence of blockage of DNA replication, which leads to collapse of replication forks and DSB formation. These DSBs are thought to be crucial downstream apoptosis-tr…

Programmed cell deathDNA RepairDNA repairDNA damageApoptosisp38 Mitogen-Activated Protein KinasesAnimalsHumansE2F1Molecular BiologybiologyCaspase 2DNA replicationDNAProliferating cell nuclear antigenCaspasesbiology.proteinCancer researchMolecular MedicineDNA mismatch repairTumor Suppressor Protein p53biological phenomena cell phenomena and immunityProto-Oncogene Proteins c-aktAtaxia telangiectasia and Rad3 relatedDNA DamageMutagensSignal TransductionTrends in Molecular Medicine
researchProduct

Synthesis and characterization of polyaspartamide copolymers obtained by ATRP for nucleic acid delivery

2014

Abstract Nucleic acid molecules such as small interfering RNAs (siRNAs) and plasmidic DNAs (pDNAs) have been shown to have the potential to be of therapeutic value in different human diseases. Their practical use is however compromised by the lack of appropriate release systems. Delivered as naked molecules, siRNAs/pDNAs are rapidly degraded by extracellular nucleases thus considerably reducing the amount of molecule which can reach the target cells. Additionally, the anionic charge of the phosphate groups present on the siRNAs/pDNAs backbone, disfavors the interaction with the negatively charged surface of the cell membrane. In this paper we describe the generation of a novel polymer able …

Small interfering RNACell SurvivalPharmaceutical ScienceATRPMethacrylateTransfectionsiRNA; deliveryPolymerizationchemistry.chemical_compoundMiceSiRNA delivery; DNA delivery; Polyaspartamide; ATRPCell Line TumorPolymer chemistryCopolymerAnimalsHumansRNA MessengerRNA Small Interferingchemistry.chemical_classificationAtom-transfer radical-polymerizationPolymerDNACombinatorial chemistryPolyaspartamideMonomerchemistryPolymerizationsiRNANucleic acidSiRNA deliveryMethacrylatesdeliveryPeptidesE2F1 Transcription FactorDNA deliveryPlasmids
researchProduct

Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription

2011

International audience; The inhibitor of apoptosis protein cIAP1 (cellular inhibitor of apoptosis protein-1) is a potent regulator of the tumor necrosis factor (TNF) receptor family and NF-B signaling pathways in the cytoplasm. However, in some primary cells and tumor cell lines, cIAP1 is expressed in the nucleus, and its nuclear function remains poorly understood. Here, we show that the N-terminal part of cIAP1 directly interacts with the DNA binding domain of the E2F1 transcription factor. cIAP1 dramatically increases the transcriptional activity of E2F1 on synthetic and CCNE promoters. This function is not conserved for cIAP2 and XIAP, which are cytoplasmic proteins. Chromatin immunoprec…

Transcription GeneticCellular differentiation[SDV]Life Sciences [q-bio]Cyclin ACyclin A[SDV.BC]Life Sciences [q-bio]/Cellular BiologyResponse ElementsInhibitor of apoptosisBiochemistryInhibitor of Apoptosis ProteinsMice03 medical and health sciences0302 clinical medicineCyclin EAnimalsHumansE2F1Gene SilencingE2F[SDV.BC] Life Sciences [q-bio]/Cellular BiologyMolecular BiologyCell Proliferation030304 developmental biologyCell Nucleus0303 health sciencesbiologyE2F1 Transcription FactorCell BiologyCell cycleMolecular biologyProtein Structure Tertiary3. Good healthCell biology[SDV] Life Sciences [q-bio]030220 oncology & carcinogenesisbiology.proteinbiological phenomena cell phenomena and immunityChromatin immunoprecipitationE2F1 Transcription FactorHeLa Cells
researchProduct

ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1).

2000

The Myc promoter-binding protein-1 (MBP-1) is a 37-38 kDa protein that binds to the c-myc P2 promoter and negatively regulates transcription of the protooncogene. MBP-1 cDNA shares 97% similarity with the cDNA encoding the glycolytic enzyme alpha-enolase and both genes have been mapped to the same region of human chromosome 1, suggesting the hypothesis that the two proteins might be encoded by the same gene. We show here data indicating that a 37 kDa protein is alternatively translated from the full-length alpha-enolase mRNA. This shorter form of alpha-enolase is able to bind the MBP-1 consensus sequence and to downregulate expression of a luciferase reporter gene under the control of the c…

CytoplasmTranscriptional repressionRecombinant Fusion ProteinsBiophysicsEnolaseCodon InitiatorDown-RegulationBiologyAlternative translationResponse ElementsTransfectionBiochemistryCell LineGene productHSPA4Proto-Oncogene Proteins c-mycStructural BiologyHSPA2GeneticsBiomarkers TumorE2F1AnimalsHumansSOCS6Genes Tumor SuppressorDNA bindingPromoter Regions GeneticMolecular BiologyYY1Tumor Suppressor ProteinsNuclear ProteinsCell BiologyDNAMolecular biologyGPS2Neoplasm ProteinsDNA-Binding ProteinsMolecular WeightRepressor ProteinsAlternative SplicingGATAD2BChromosomes Human Pair 1Phosphopyruvate HydrataseProtein BiosynthesisPeptidesProtein BindingFEBS letters
researchProduct

Screening for Autoantibodies to Tissue Transglutaminase Reveals a Low Prevalence of Celiac Disease in Blood Donors with Cryptogenic Hypertransaminase…

2001

Patients with chronic cryptogenic hypertransaminasemia are at high risk of developing celiac disease (CD). In fact, among the various serological disorders, CD patients at onset frequently present hypertransaminasemia. In this study, we evaluated usefulness and reliability of the new test for antitissue transglutaminase (tTG) in screening for CD as well as in estimating the prevalence of CD in a population of blood donors presenting unexplained hypertransaminasemia at donation. Controls were 180 consecutive healthy donors without hypertransaminasemia and 20 CD patients with known antiendomysial antibody (EmA) positivity. Out of 22,204 blood donors over a period of 2 years, we found 258 subj…

AdultMaleBlood donormedicine.medical_specialtyTissue transglutaminasePopulationE2F6 Transcription FactorBlood DonorsEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityGastroenterologyCoeliac diseaseSerologyIntestinal mucosaInternal medicineImmunopathologyBiopsyPrevalencemedicineHumansCeliac diseaseIntestinal MucosaFluorescent Antibody Technique IndirecteducationTransaminasesAutoantibodieseducation.field_of_studyTransglutaminasesbiologymedicine.diagnostic_testbusiness.industryGastroenterologyAutoantibodyReproducibility of ResultsMiddle Agedmedicine.diseaseTransglutaminaseRepressor ProteinsImmunologybiology.proteinFemalebusinessTranscription FactorsDigestion
researchProduct

Analysis of E2F1 by clAP1

2017

The cellular inhibitor of Apoptosis 1 (cIAP1) behaves as an E3 ubiquitin ligase and has oncogenic properties. Previously, our team has shown that cIAP1 can regulate the E2F1 transcription factor activity. My research project has been focused on deepening our current knowledge on this interaction. Firstly, we characterized the E2F1-cIAP1 interaction, then we analyzed the regulation of E2F1 by cIAP1 and finally assessed the importance of the cIAP1-E2F1 interaction for the oncogenic properties of cIAP1. I have demonstrated a interaction of E2F1 with the hydrophobic pocket of the BIR3 domain of cIAP1. Moreover, I highlighted that the alpha 1 helix of the BIR3 domain is mandatory for the stabili…

[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyCIAP1E2F1UbiquitinylationIAP-Binding-MotifIBM
researchProduct

Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1.

2008

Paclitaxel (PTX) is an anticancer drug currently in phase II clinical trials. This study shows for the first time that low doses of PTX (5 nM) potently induce apoptosis in human retinoblastoma Y79 cells. The effect of PTX is accompanied by a potent induction of E2F1 which appears to play a critical role in the effects induced by PTX. PTX induced a dose- and time-dependent effect, with G2/M arrest, cyclines A, E and B1 accumulation and a marked modification in the status of Cdc2-cyclin B1 complex, the major player of the G2/M checkpoint. Apoptosis followed G2/M arrest. An early and prolonged increase in p53 expression with its stabilization by phosphorylation and acetylation and its nuclear …

Cyclin-Dependent Kinase Inhibitor p21G2 Phaseendocrine systemCancer ResearchProgrammed cell deathPaclitaxelApoptosisBiologyretinoblastoma apoptosis paclitaxelp14arfSettore BIO/10 - BiochimicaCell Line TumorE2F1HumansFragmentation (cell biology)PhosphorylationMembrane Potential MitochondrialRetinoblastomaCell cycleAntineoplastic Agents PhytogenicUp-RegulationGene Expression Regulation NeoplasticOncologyApoptosisCancer researchPhosphorylationApoptosomeTumor Suppressor Protein p53Cell DivisionE2F1 Transcription FactorInternational journal of oncology
researchProduct

Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer

2021

Given the lack of effective treatments for Hepatocellular carcinoma (HCC), the development of novel therapeutic approaches is very urgent. Here, siRNAs were delivered to HCC cells by a synthetic polymer containing α,β-poly-(N-2-hydroxyethyl)-D,L-aspartamide-(PHEA) derivatized with diethylene triamine (DETA) and bearing in the side chain galactose (GAL) linked via a polyethylene glycol (PEG) to obtain (PHEA-DETA-PEG-GAL, PDPG). The GAL residue allows the targeting to the asialo-glycoprotein receptor (ASGPR), overexpressed in HCC cells compared to normal hepatocytes. Uptake studies performed using a model siRNA or a siRNA targeted against the enhanced green fluorescence protein, demonstrated …

Small interfering RNACarcinoma HepatocellularPolymersHepatocellular carcinomaCellASGPR targeted delivery; E2F1; Eukaryotic elongation Factor 1A; Hepatocellular carcinoma; siRNAPharmaceutical Science02 engineering and technologyEukaryotic elongation Factor 1AMice03 medical and health sciencesIn vivomedicineAnimalsE2F1RNA Small InterferingReceptor030304 developmental biology0303 health sciencesChemistryLiver NeoplasmsASGPR targeted deliveryGalactose021001 nanoscience & nanotechnologymedicine.diseasedigestive system diseasesEukaryotic translation elongation factor 1 alpha 1In vitromedicine.anatomical_structureE2F1Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomasiRNACancer research0210 nano-technology
researchProduct